A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure - Trial NCT05952089
Access comprehensive clinical trial information for NCT05952089 through Pure Global AI's free database. This Phase 1 trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 16 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
Phase 1
Jul 17, 2023
Feb 28, 2024
Primary Outcome
Maximum observed plasma concentration (Cmax),Area under the plasma concentration time curve from time zero extrapolated to infinite time (AUC[INF]),Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Summary
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug
 levels of midazolam in participants with heart failure with reduced ejection fraction
 (HFrEF).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05952089
Non-Device Trial